- Home
- NRIX
as 12-20-2024 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.3B | IPO Year: | 2020 |
| Target Price: | $30.29 | AVG Volume (30 days): | 988.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.65 - $29.56 | Next Earning Date: | 02-13-2025 |
| Revenue: | $56,424,000 | Revenue Growth: | -17.76% |
| Revenue Growth (this year): | -27.57% | Revenue Growth (next year): | 5.92% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Nov 4 '24 | Sell | $25.00 | 3,290 | $82,250.00 | 28,084 | |
| van Houte Hans | NRIX | Chief Financial Officer | Nov 1 '24 | Sell | $24.28 | 3,546 | $86,083.41 | 33,724 | |
| Ring Christine | NRIX | Chief Legal Officer | Nov 1 '24 | Sell | $24.28 | 5,760 | $139,866.62 | 28,084 | |
| van Houte Hans | NRIX | Chief Financial Officer | Oct 30 '24 | Sell | $24.31 | 2,368 | $57,554.24 | 33,724 | |
| Hansen Gwenn | NRIX | Chief Scientific Officer | Oct 30 '24 | Sell | $24.31 | 3,437 | $83,536.29 | 50,670 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 30 '24 | Sell | $24.31 | 4,182 | $101,643.51 | 28,084 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 14 '24 | Sell | $25.00 | 3,290 | $82,250.00 | 28,084 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 1 '24 | Sell | $22.50 | 5,760 | $128,017.33 | 28,084 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Nurix Therapeutics Says Waldenstrom Macroglobulinemia Drug Granted Fast Track Designation by FDA
GlobeNewswire
3 days ago
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Insider Monkey
11 days ago
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
GlobeNewswire
13 days ago
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
MT Newswires
16 days ago
BMO Capital Initiates Nurix Therapeutics at Outperform With $35 Price Target
Insider Monkey
18 days ago
Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
GlobeNewswire
20 days ago
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire
a month ago
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.